<!DOCTYPE HTML>
<!DOCTYPE html PUBLIC "" ""><HTML lang="en" lang="en" xml:lang="en" xmlns="http://www.w3c.org/1999/xhtml"><HEAD><META 
content="IE=11.0000" http-equiv="X-UA-Compatible">
     
<META http-equiv="content-type" content="text/html; charset=utf-8">     
<TITLE>L36_B</TITLE>     
<META name="title" content="NHANES 2001-2002: Syphilis-IgG, Syphilis Rapid Plasma Reagin (RPR) &amp; Treponema pallidum Particle Agglutination (TP-PA) Data Documentation, Codebook, and Frequencies"> 
    
<STYLE type="text/css">
					.nhanes-doc { font: 75% Verdana, Arial, Helvetica, sans-serif; }

					.nhanes-doc h1 {
					color: #0c5205;
					font-family: "Trebuchet MS", Arial, sans-serif;
					font-size: 2em;
					font-weight: normal;
					margin-bottom: 10px;
					margin-top: 0;
					}

					.nhanes-doc h2 {
					color: #0c5205;
					font-family: "Trebuchet MS", Arial, sans-serif;
					font-size: 1.6em;
					font-weight: normal;
					}

					.nhanes-doc h3 {
					color: #000;
					font-family: "Trebuchet MS", Arial, sans-serif;
					font-size: 1.5em;
					font-weight: normal;
					}

					.nhanes-doc h3.vartitle {
					background-color: #c1d5b0;
					padding: 6px 12px;
					}

					.nhanes-doc h4 {
					color: #000;
					font-family: "Trebuchet MS", Arial, sans-serif;
					font-size: 1.3em;
					font-weight: bold;
					}

					.nhanes-doc h5 {
					color: #000;
					font-family: Verdana, Arial, Helvetica, sans-serif;
					font-size: 1em;
					font-weight: bold;
					}

					.nhanes-doc h5.specialnote {
					color: #000;
					font-family: Verdana, Arial, Helvetica, sans-serif;
					font-size: 1.2em;
					font-style: italic;
					font-weight: bold;
					}

					.nhanes-doc a {
					color: #039;
					text-decoration: none;
					}

					.nhanes-doc p {
					font-family: Verdana, Arial, Helvetica, sans-serif;
					font-size: 1em;
					line-height: 1.33em;
					margin: 0 3em 1em;
					padding: 0;
					text-align: left;
					}

					.nhanes-doc ul {
					list-style-type: disc;
					margin: 0 3em 1em;
					padding: 0;
					}

					.nhanes-doc ol {
					list-style-type: decimal;
					margin: 0;
					overflow: hidden;
					padding: 0;
					padding-left: 2em;
					}

					.nhanes-doc li {
					margin-left: 1.5em;
					margin-top: 0.7em;
					}

					.nhanes-doc table {
					border: #000 1px solid;
					border-collapse: collapse;
					margin: 0 auto 1em;
					max-width: 600px;
					padding: 2px;
					page-break-inside: avoid;
					table-layout: auto;
					}

					.nhanes-doc th {
					background: #f4f4e1;
					border: #000 1px solid;
					font-family: Verdana, Arial, Helvetica, sans-serif;
					padding: 5px;
					text-align: center;
					vertical-align: top;
					}

					.nhanes-doc th.rowheader {
					background: #f4f4e1;
					border: #000 1px solid;
					font-family: Verdana, Arial, Helvetica, sans-serif;
					padding: 5px;
					text-align: center;
					vertical-align: top;
					}

					.nhanes-doc td {
					border: #000 1px solid;
					font-family: Verdana, Arial, Helvetica, sans-serif;
					padding: 5px;
					text-align: left;
					vertical-align: top;
					}

					.nhanes-doc td.values2 {
					text-align: RIGHT;
					vertical-align: top;
					}

					.nhanes-doc table caption {
					font-weight: bold;
					padding-bottom: 0.5em;
					}

					.nhanes-doc div#wrapper { width: 650px; }

					.nhanes-doc div#toc {
					border: solid 1px #CCC;
					float: left;
					height: 95%;
					left: 750px;
					overflow: hidden;
					position: fixed;
					top: 10px;
					width: 400px;
					z-index: 10;
					}

					.nhanes-doc div#toc h3 {
					background-color: #f4f4e1;
					border-bottom: solid 1px #ccc;
					letter-spacing: 8px;
					margin: 0;
					padding: 8px;
					text-align: center;
					text-transform: uppercase;
					}

					.nhanes-doc div#toc-scroll {
					height: calc(100% - 1.5em);
					overflow: scroll;
					width: 100%;
					}

					.nhanes-doc div#toc li {
					margin-left: -0.5em;
					margin-right: -0.5em;
					}

					.nhanes-doc div#PageHeader {
					border-bottom: thin solid #999;
					margin-bottom: 12px;
					width: 650px;
					}

					.nhanes-doc div#Sections { width: 650px; }

					.nhanes-doc div#Codebook { width: 650px; }

					.nhanes-doc div#Codebook dl {
					margin: 2em 0 10px 40px;
					padding: 0;
					width: 600px;
					display: table;
					}

					.nhanes-doc div#Codebook dt {
					float: left;
					font-weight: bold;
					margin: 0;
					padding: 0.5em;
					width: 150px;
					display: table-cell;
					}

					.nhanes-doc div#Codebook dd {
					float: left;
					margin: 0;
					padding: 0.5em;
					width: 420px;
					display: table-cell;
					}

					.nhanes-doc div#References {
					page-break-after: always;
					width: 650px;
					}

					.nhanes-doc div#Appendix {
					page-break-after: always;
					width: 650px;
					}

					.nhanes-doc table.values {
					border: 2px;
					left: 20px;
					margin-bottom: 20px;
					page-break-inside: avoid;
					position: relative;
					width: 600px;
					}

					.nhanes-doc span.file-size { color: gray; }

					.nhanes-doc .pagebreak {
					background-color: transparent;
					display: block;
					page-break-after: always;
					page-break-inside: avoid;
					}
				</STYLE>
     
<STYLE type="text/css" media="print">
					.nhanes-doc div#toc { display: none; }
				</STYLE>
   </HEAD>   
<BODY class="nhanes-doc">
<DIV id="toc">
<H3>Table of Contents</H3>
<DIV id="toc-scroll">
<UL>
  <LI><A href="#Component_Description">Component Description</A>           </LI>
  <LI><A href="#Eligible_Sample">Eligible Sample</A>           </LI>
  <LI><A href="#Description_of_Laboratory_Methodology">Description of Laboratory 
  Methodology</A>           </LI>
  <LI><A href="#Laboratory_Quality_Assurance_and_Monitoring">Laboratory Quality 
  Assurance and Monitoring</A>           </LI>
  <LI><A href="#Data_Processing_and_Editing">Data Processing and Editing</A>     
        </LI>
  <LI><A href="#Analytic_Notes">Analytic Notes</A>           </LI>
  <LI><A href="#References">References</A>           </LI>
  <LI><A href="#Codebook">Codebook</A>             
  <UL id="CodebookLinks">
    <LI><A href="#SEQN">SEQN - Respondent sequence number</A>               
</LI>
    <LI><A href="#LBXSY1">LBXSY1 - Syphilis IgG EIA</A>               </LI>
    <LI><A href="#LBDSY3">LBDSY3 - Syphilis RPR Titer Level</A>               
    </LI>
    <LI><A href="#LBDSY4">LBDSY4 - Syphilis TP-PA</A>               
</LI></UL></LI></UL></DIV></DIV>
<DIV id="wrapper">
<DIV id="PageHeader">
<H1>National Health and Nutrition Examination Survey</H1>
<H2>2001-2002 Data Documentation, Codebook, and Frequencies</H2>
<H3>Syphilis-IgG, Syphilis Rapid Plasma Reagin (RPR) &amp; Treponema pallidum 
Particle Agglutination (TP-PA) (L36_B)</H3>
<H4> Data File: L36_B.xpt</H4>
<H5 class="left">First Published: September 2003</H5>
<H5 class="right">Last Revised: May 2004</H5></DIV>
<DIV id="Sections">
<H2 id="Component_Description">Component Description</H2>
<P>Although there has been a marked decrease in the number of primary and 
secondary syphilis cases in the United States, there has been very little 
decrease in the number of reported cases of late latent and tertiary syphilis 
over the past 20 years. This suggests that there may be a large pool of infected 
but asymptomatic persons. Although the primary and secondary stages of syphilis 
are infectious and associated with fetal wastage and the congenital syphilis 
syndrome, the tertiary stage is associated with a vasculitis that may cause 
neurologic and cardiovascular manifestations and other chronic problems. 
Similarly, primary and secondary syphilis increase the risk of HIV acquisition 
and transmission while latent disease may be associated with progression of HIV 
disease to AIDS and more prominent neurologic disease in HIV-infected persons. 
Despite the importance of syphilis as a risk factor for both chronic disease and 
the progression of HIV infection, there has not been a population-based measure 
of syphilis prevalence for the United States since 1980. Because these are often 
asymptomatic stages of infection and may lead to severe neurologic or 
cardiovascular complications, it is important to document a decrease in the late 
stages of syphilis that have resulted from our extraordinary efforts to reduce 
primary and secondary syphilis. NHANES offers a unique opportunity to estimate 
the prevalence of reactive serologic tests as an estimate of the prevalence of 
syphilis infections in the general population, to identify and confirm risk 
factors for syphilis, to confirm the risk for HIV infection and HIV-related 
neurologic disease among Americans with syphilis, and to monitor trends in 
prevalence as syphilis detection and treatment programs are established and 
expanded.</P>
<H2 id="Eligible_Sample">Eligible Sample</H2>
<P>Participants aged 18 to 49 years were tested.</P>
<H2 id="Description_of_Laboratory_Methodology">Description of Laboratory 
Methodology</H2>
<P><STRONG>Syphilis-G enzyme immunoassay (EIA)</STRONG> </P>
<P>The Captia Syphilis-G enzyme immunoassay (EIA) is an indirect method for the 
detection of IgG antibodies to <EM>Treponema pallidum </EM>(Pope&nbsp;et al., 
1998; Lefevre et al., 1990; Nayar et al., 1993; Silletti&nbsp;et al., 
1995;&nbsp;Young et al., 1995). Currently, CDC recommends that the test be used 
in the clinical laboratory as a confirmatory test for the diagnosis of syphilis. 
However, the test may be used as a screening test and is FDA approved for such 
use in clinical laboratories and blood banks. <EM>T. pallidum</EM> antigens are 
coated onto the wells of a 96-well microtiter plate. A dilution of the patient’s 
serum is added to the well to allow any <EM>T. pallidum</EM> specific antibodies 
present to bind to the treponemal antigens. Biotinylated anti-human IgG labeled 
with strepavidin-peroxidase is used to detect the patient’s antibody. After 
rinsing off the excess antibodies, an enzyme substrate is added for detection. 
If the patient has antibodies to <EM>T. pallidum</EM>, a color reaction takes 
place. The intensity of the color development is proportional to the amount of 
antibody present. This color change can then be read using a plate reader, which 
eliminates subjective interpretation of the results. </P>
<P><STRONG>Rapid plasma reagin (RPR)</STRONG> </P>
<P>The rapid plasma reagin (RPR) 18-mm circle card test is a macroscopic, 
nontreponemal flocculation card test used to screen for syphilis (Portnoy et 
al., 1962; Portnoy et al., 1963; Portnoy et al., 1965; Hynson Westcott and 
Dunning et al., 1977). The antigen is prepared from a modified Venereal Disease 
Research Laboratory (VDRL) antigen suspension containing choline chloride to 
eliminate the need to heat inactivate serum, ethylene-diamine-tetra- acetic acid 
(EDTA) to enhance the stability of the suspension, and finely divided charcoal 
particles as a visualizing agent. In the test, the RPR antigen is mixed with 
unheated or heated serum or with unheated plasma on a plastic-coated card. The 
RPR test measures IgM and IgG antibodies to lipoidal material released from 
damaged host cells as well as to lipoprotein-like material, and possibly 
cardiolipin released from the treponemes (Matthews et al., 1979; Belisle&nbsp;et 
al., 1994). The anti lipoidal antibodies are antibodies that are produced not 
only as a consequence of syphilis and other treponemal diseases, but also in 
response to nontreponemal diseases of an acute and chronic nature in which 
tissue damage occurs (Catterall et al., 1972). If antibodies are present, they 
combine with the lipid particles of the antigen, causing them to agglutinate. 
The charcoal particles coagglutinate with the antibodies and show up as black 
clumps against the white card. If antibodies are not present, the test mixture 
is uniformly gray. The test can be purchased in kit form or in component parts 
from many commercial sources. Without some other evidence for the diagnosis of 
syphilis, a reactive nontreponemal test does not confirm <EM>T. pallidum</EM> 
infection. </P>
<P><STRONG><EM>Treponema pallidum </EM>particle agglutination (TP-PA)</STRONG> 
</P>
<P>The Serodia <EM>Treponema pallidum</EM> particle agglutination (TP-PA) test 
is a treponemal test for the serologic detection of antibodies to the various 
species and subspecies of pathogenic Treponema, the causative agents of 
syphilis, yaws, pinta, bejel, and endemic syphilis. The test is a passive 
agglutination procedure based on the agglutination of gel particles sensitized 
with <EM>T. pallidum</EM> antigens by antibodies found in the patient's serumm 
(Deguchi et al., 1994; Pope et al., 2000; Pope et al., 2000).&nbsp;The test is 
intended as a confirmatory test to replace the microhemagglutination assay for 
antibodies to <EM>T. pallidum</EM> (MHA-TP). </P>
<P>Serum containing antibodies to pathogenic treponemes react with gel particles 
sensitized with sonicated <EM>T. pallidum</EM>, Nichols strain (the antigen), to 
form a smooth mat of agglutinated gel particles in the microtiter tray well. If 
antibodies are not present, the particles settle to the bottom of the tray well, 
forming a characteristic compact button of unagglutinated particles. The 
unsensitized gel particle control well for each serum should also show this 
compact button, or the absence of agglutination. </P>
<P>The TP-PA test is used to confirm the reactive results (Pope et al., 2000; 
Pope et al., 2000) of a nontreponemal screening test for syphilis, such as the 
Venereal Disease Research Laboratory (VDRL) slide test, or as a diagnostic test 
in patients with a nonreactive nontreponemal test but with signs or symptoms 
suggestive of late syphilis. </P>
<P><STRONG>Testing algorithm for NHANES specimens</STRONG> </P>
<P>All serum specimens were tested for IgG antibody by the EIA assay. If results 
of this assay were positive or equivocal, the specimens were tested using the 
RPR test. If the RPR test was negative, the TP-PA test was performed on the 
sample. </P>
<P><STRONG>Suggested interpretation of laboratory results.</STRONG> </P>
<P>LBXSY1= Syphilis-G enzyme immunoassay (EIA) <BR> LBDSY3= Rapid plasma reagin 
(RPR) <BR> LBDSY4= <EM>Treponema pallidum</EM> particle agglutination (TP-PA) 
</P>
<P>Recent positive syphilis infection: <BR> (LBXSY =1 or LBXSY1=3) and (LBDSY3 
&gt;=8) </P>
<P>Remote positive syphilis infection: <BR> (LBXSY1 =1 or LBXSY1=3) and (0&lt;= 
LBDSY3 &lt;8) and (LBDSY4=1) </P>
<P>No infection: <BR> LBXSY1=2 </P>
<P>OR </P>
<P>(LBXSY1=1 or LBXSY1=3) and (0&lt;=LBDSY3&lt;8) and (LBDSY4=2)</P>
<H2 id="Laboratory_Quality_Assurance_and_Monitoring">Laboratory Quality 
Assurance and Monitoring</H2>
<P>The NHANES quality control and quality assurance protocols (QA/QC) meet the 
1988 Clinical Laboratory Improvement Act mandates. Detailed quality control and 
quality assurance instructions are discussed in the NHANES Laboratory/Medical 
Technologists Procedures Manual (LPM). Read the LABDOC file for detailed QA/QC 
protocols.</P>
<H2 id="Data_Processing_and_Editing">Data Processing and Editing</H2>
<P>Serum specimens were processed, stored and shipped to Division of STD 
Prevention Laboratory, National Center for HIV/AIDS, Viral Hepatitis, STD, and 
TB Prevention,&nbsp;Centers for Disease Control and Prevention, Atlanta, 
Georgia. Detailed specimen collection and processing instructions are discussed 
in the NHANES Laboratory/Medical Technologists Procedures Manual (LPM). Read the 
LABDOC file for detailed data processing and editing protocols. The analytical 
methods are described in the Description of the Laboratory Methodology 
section.</P>
<H2 id="Analytic_Notes">Analytic Notes</H2>
<P>The analysis of NHANES 2001-2002 laboratory data must be conducted with the 
key survey design and basic demographic variables. The NHANES 2001-2002 
Household Questionnaire Data Files contain demographic data, health indicators, 
and other related information collected during household interviews. They also 
contain all survey design variables and sample weights for these age groups. The 
phlebotomy file includes auxiliary information such as the conditions precluding 
venipuncture. The household questionnaire and phlebotomy files may be linked to 
the laboratory data file using the unique survey participant identifier 
SEQN.</P></DIV>
<DIV id="References">
<H2>References</H2>
<UL>
  <LI>Belisle JT, Brandt ME et al. Fatty acids of Treponema pallidum and 
  Borrelia burgdorferi lipoproteins. J Bacteriol 1994;176:2151-7.</LI>
  <LI>Catterall, RD. Presidential address to the M.S.S.V.D.: Systemic disease 
  and the biological false-positive reaction. Br J Vener Dis 1972;48:1-12.</LI>
  <LI>Deguchi M, Hosotsubo H, Yamashita N, Ohmine T and Asari S. Evaluation of 
  gelatin particle agglutination method for detection of Treponema pallidum 
  antibody. Journal of the Japanese Association of Infectious Diseases 1994; 
  68:1271-7.</LI>
  <LI>Hynson Westcott and Dunning, RPR Macro-Vue Card Test - Procedures Manual. 
  Baltimore, MD 1977.</LI>
  <LI>Lefevre JC, Bertrand MA, and Bauriaud R. Evaluation of the Captia enzyme 
  immunoassays for detection of immunoglobulins G and M to Treponema pallidum in 
  syphilis. J Clin Microbiol 1990;28:1704-7.</LI>
  <LI>Matthews HM, Yang TK, Jenkin HM. Unique lipid composition of Treponema 
  pallidum (Nichols virulent strain). Infect Immun 1979;24:713-9.</LI>
  <LI>Nayar R, and Campos JM. Evaluation of the DCL Syphilis-G enzyme 
  immunoassay test kit for the serologic diagnosis of syphilis. Amer J Clin 
  Pathol 1993;99:282-5.</LI>
  <LI>Pope V and Fears MB. Serodia Treponema pallidum passive particle 
  agglutination (TP-PA) test, In: Larsen SA, Pope V, Johnson, RE, and Kennedy 
  EJ, Jr. (eds). A Manual of Tests for Syphilis, Supplement. American Public 
  Health Association, Washington, DC. 2000:363-78.</LI>
  <LI>Pope V, Fears MB, Morrill WE, Castro A, and Kikkert SE. 2000. Comparison 
  of the Serodia Treponema pallidum particle agglutination, Captia Syphilis-G, 
  and SpiroTek Reagin II tests with standard test techniques for diagnosis of 
  syphilis. J Clin Microbiol 38:2543-2545.</LI>
  <LI>Pope V, Fears MB. Captia Syphilis-G: an enzyme immunoassay for treponemal 
  antibodies. In: Larsen SA, Pope V, Johnson RE, Kennedy EJ (ed.) A manual of 
  tests for syphilis. American Public Health Association, Washington, DC. 
  1998:332-45.</LI>
  <LI>Portnoy J, Brewer JH, Harris A. Rapid plasma reagin card test for syphilis 
  and other treponematoses. Public Health Rep 1962;77:645-52.</LI>
  <LI>Portnoy J. A note on the performance of modifications of the rapid plasma 
  reagin (RPR) card test for syphilis, for use in large scale testing. Public 
  Hlth Lab 1965;23:43.</LI>
  <LI>Portnoy J. Modifications of the rapid plasma reagin (RPR) card test for 
  syphilis, for use in large scale testing. Am J Clin Pathol 1963;40:473-9.</LI>
  <LI>Silletti RP. Comparison of CAPTIA Syphilis G enzyme immunoassay with rapid 
  plasma reagin test for detection of syphilis. J Clin Microbiol 
  1995;33:1829-31.</LI></UL></DIV>
<DIV id="Codebook">
<H2>Codebook and Frequencies</H2>
<DIV class="pagebreak">
<H3 class="vartitle" id="SEQN">SEQN - Respondent sequence number</H3>
<DL>
  <DT>Variable Name: </DT>
  <DD class="info">SEQN</DD>
  <DT>SAS Label: </DT>
  <DD>Respondent sequence number</DD>
  <DT>English Text: </DT>
  <DD class="info">Respondent sequence number.</DD>
  <DT>Target: </DT>
  <DD> Both males and females 18 YEARS -			49 YEARS</DD></DL></DIV>
<DIV class="pagebreak">
<H3 class="vartitle" id="LBXSY1">LBXSY1 - Syphilis IgG EIA</H3>
<DL>
  <DT>Variable Name: </DT>
  <DD class="info">LBXSY1</DD>
  <DT>SAS Label: </DT>
  <DD>Syphilis IgG EIA</DD>
  <DT>English Text: </DT>
  <DD class="info">Syphilis IgG EIA</DD>
  <DT>Target: </DT>
  <DD> Both males and females 18 YEARS -			49 YEARS</DD></DL>
<TABLE class="values">
  <THEAD>
  <TR>
    <TH class="values" scope="column">Code or Value</TH>
    <TH class="values" scope="column">Value Description</TH>
    <TH class="values" scope="column">Count</TH>
    <TH class="values" scope="column">Cumulative</TH>
    <TH class="values" scope="column">Skip to Item</TH></TR></THEAD>
  <TBODY>
  <TR>
    <TD class="values" scope="row">1</TD>
    <TD class="values">Positive</TD>
    <TD align="right" class="values">59</TD>
    <TD align="right" class="values">59</TD>
    <TD class="values"></TD></TR>
  <TR>
    <TD class="values" scope="row">2</TD>
    <TD class="values">Negative</TD>
    <TD align="right" class="values">2965</TD>
    <TD align="right" class="values">3024</TD>
    <TD class="values"></TD></TR>
  <TR>
    <TD class="values" scope="row">3</TD>
    <TD class="values">Indeterminate</TD>
    <TD align="right" class="values">4</TD>
    <TD align="right" class="values">3028</TD>
    <TD class="values"></TD></TR>
  <TR>
    <TD class="values" scope="row">.</TD>
    <TD class="values">Missing</TD>
    <TD align="right" class="values">271</TD>
    <TD align="right" class="values">3299</TD>
    <TD class="values"></TD></TR></TBODY></TABLE></DIV>
<DIV class="pagebreak">
<H3 class="vartitle" id="LBDSY3">LBDSY3 - Syphilis RPR Titer Level</H3>
<DL>
  <DT>Variable Name: </DT>
  <DD class="info">LBDSY3</DD>
  <DT>SAS Label: </DT>
  <DD>Syphilis RPR Titer Level</DD>
  <DT>English Text: </DT>
  <DD class="info">Syphilis RPR (rapid plasmin test) titer level</DD>
  <DT>Target: </DT>
  <DD> Both males and females 18 YEARS -			49 YEARS</DD></DL>
<TABLE class="values">
  <THEAD>
  <TR>
    <TH class="values" scope="column">Code or Value</TH>
    <TH class="values" scope="column">Value Description</TH>
    <TH class="values" scope="column">Count</TH>
    <TH class="values" scope="column">Cumulative</TH>
    <TH class="values" scope="column">Skip to Item</TH></TR></THEAD>
  <TBODY>
  <TR>
    <TD class="values" scope="row">0 to 128</TD>
    <TD class="values">Range of Values</TD>
    <TD align="right" class="values">63</TD>
    <TD align="right" class="values">63</TD>
    <TD class="values"></TD></TR>
  <TR>
    <TD class="values" scope="row">.</TD>
    <TD class="values">Missing</TD>
    <TD align="right" class="values">3236</TD>
    <TD align="right" class="values">3299</TD>
    <TD class="values"></TD></TR></TBODY></TABLE></DIV>
<DIV class="pagebreak">
<H3 class="vartitle" id="LBDSY4">LBDSY4 - Syphilis TP-PA</H3>
<DL>
  <DT>Variable Name: </DT>
  <DD class="info">LBDSY4</DD>
  <DT>SAS Label: </DT>
  <DD>Syphilis TP-PA</DD>
  <DT>English Text: </DT>
  <DD class="info">Syphilis treponemal pallidum agglutin (TPA)</DD>
  <DT>Target: </DT>
  <DD> Both males and females 18 YEARS -			49 YEARS</DD></DL>
<TABLE class="values">
  <THEAD>
  <TR>
    <TH class="values" scope="column">Code or Value</TH>
    <TH class="values" scope="column">Value Description</TH>
    <TH class="values" scope="column">Count</TH>
    <TH class="values" scope="column">Cumulative</TH>
    <TH class="values" scope="column">Skip to Item</TH></TR></THEAD>
  <TBODY>
  <TR>
    <TD class="values" scope="row">1</TD>
    <TD class="values">Positive</TD>
    <TD align="right" class="values">34</TD>
    <TD align="right" class="values">34</TD>
    <TD class="values"></TD></TR>
  <TR>
    <TD class="values" scope="row">2</TD>
    <TD class="values">Negative</TD>
    <TD align="right" class="values">24</TD>
    <TD align="right" class="values">58</TD>
    <TD class="values"></TD></TR>
  <TR>
    <TD class="values" scope="row">3</TD>
    <TD class="values">Indeterminate</TD>
    <TD align="right" class="values">0</TD>
    <TD align="right" class="values">58</TD>
    <TD class="values"></TD></TR>
  <TR>
    <TD class="values" scope="row">.</TD>
    <TD class="values">Missing</TD>
    <TD align="right" class="values">3241</TD>
    <TD align="right" class="values">3299</TD>
    <TD class="values"></TD></TR></TBODY></TABLE></DIV></DIV></DIV></BODY></HTML>
